BACKGROUND: Despite the progress that has been achieved in the last years, recurrence rates in @entity43 @entity1 are still considerably high and the majority of @entity1 ultimately become candidates for second-line treatment. @entity3003 reinduction is a broadly adopted regimen in @entity1 with recurrences occurring six months or later after first-line treatment. @entity136 is among the candidates as combination partner in second-line regimens. @entity1 AND METHODS: We performed a study with escalating doses of @entity136 combined with @entity3003 in 26 @entity902 -pretreated @entity1 with recurrent @entity43 and a treatment-free interval of 6+ months. Dose-limiting @entity137 (DLT) and a maximum tolerable dose (MTD) recommendable for further trials was evaluated. RESULTS: The DLT was myelosuppression, mainly @entity882 . No dose limiting non-hematological @entity137 were observed. The MTD of @entity136 was 1,000 mg/m2 given on days 1 + 8 of a three-week schedule combined with @entity3003 AUC 4 given on day 1. The majority of evaluable @entity1 showed an objective response (62.5%), and median progression-free and overall survival were 10 and 18+ months, respectively. CONCLUSION: @entity136 - @entity3003 given according to the MTD is well tolerated and active against recurrent @entity902 -sensitive disease. A randomized trial comparing @entity3003 with or without @entity136 in @entity902 -sensitive @entity43 has already been initiated.

Second-line @entity3003 and @entity136 in XXXX sensitive @entity43 --a dose-finding study by the Arbeitsgemeinschaft Gyn  kologische Onkologie (AGO) @entity43 Study Group.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['Carboplatin', 'carboplatin'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']
@entity902 :: (MESH:D010984,Chemical) :: ['platinum']
